公开(公告)号：WO2007070546A2

公开(公告)日：2007-06-21

申请号：PCT/US2006/047473

申请日：2006-12-13

Applicant: ANIKA THERAPEUTICS, INC. ,  SADOZAI, Khalid, K. ,  TOTH, Carol, A.

Inventor： SADOZAI, Khalid, K. ,  TOTH, Carol, A.

IPC: A61F2/38 ,  A61L27/20 ,  A61K31/728 ,  A61P19/02

CPC classification number: A61L27/3843 ,  A61K9/0024 ,  A61K9/06 ,  A61K31/573 ,  A61K31/728 ,  A61K31/729 ,  A61K35/28 ,  A61K35/32 ,  A61K38/1841 ,  A61K47/36 ,  A61L27/20 ,  A61L27/227 ,  A61L27/3817 ,  A61L27/3834 ,  A61L27/48 ,  A61L27/52 ,  A61L27/56 ,  A61L2430/06 ,  C08L5/08 ,  A61K2300/00

Abstract: A composite for treating an articular defect includes a hyaluronic acid derivative; and at least one member of the group consisting of a cell, a cellular growth factor and a cellular differentiation factor, which is impregnated in, or coupled to. the hyaluronic acid derivative. In one embodiment, carboxyl functionalities of the hyaluronic acid derivative are each independently derivatized to include an N-acylurea or O-acyl isourea, or both N-acylurea and O-acyl isourea. In another embodiment, the hyaluronic acid derivative is prepared by reacting an uncrosslinked hyaluronic acid with a biscarbodimide in the presence of a pH buffer in a range of between about 4 and about 8. The composite can be used for regenerating or stimulating regeneration of meniscal tissues in a subject in need thereof.

Abstract translation: 用于治疗关节缺陷的组合物包括透明质酸衍生物; 和至少一种由细胞，细胞生长因子和细胞分化因子组成的组中的至少一种成分，所述细胞浸润或偶联于细胞生长因子和细胞分化因子。 透明质酸衍生物。 在一个实施方案中，透明质酸衍生物的羧基官能度各自独立地衍生为包括N-酰基脲或O-酰基异脲，或者N-酰基脲和O-酰基异脲二者。 在另一个实施方案中，透明质酸衍生物通过使未交联的透明质酸与双碳二亚胺在pH缓冲剂存在下在约4至约8的范围内反应来制备。该复合材料可用于再生或刺激半月板组织的再生 在有需要的主题。

公开(公告)号：WO2006029406A2

公开(公告)日：2006-03-16

申请号：PCT/US2005/032521

申请日：2005-09-09

Applicant: STRYKER CORPORATION ,  LEE, John C. ,  TOTH, Carol A.

Inventor： LEE, John C. ,  TOTH, Carol A.

IPC: A61K38/18

CPC classification number: A61K38/1875 ,  A61K48/00

Abstract: The present invention provides methods of treating bone cancer, inducing differentiation of bone tumor cells, inhibiting bone tumor growth, inducing bone tumor regression or treating a hyperproliferative cell disorder by administering a pharmaceutically effective amount of a bone morphogenic protein or a nucleic acid encoding the bone morphogenic protein.

Abstract translation: 本发明提供了通过施用药学有效量的骨形态发生蛋白或编码骨的核酸来治疗骨癌，诱导骨肿瘤细胞分化，抑制骨肿瘤生长，诱导骨肿瘤消退或治疗过度增殖性细胞病症的方法 形态发生蛋白。

公开(公告)号：WO2007070546A3

公开(公告)日：2007-08-16

申请号：PCT/US2006047473

申请日：2006-12-13

Applicant: ANIKA THERAPEUTICS INC ,  SADOZAI KHALID K ,  TOTH CAROL A

Inventor： SADOZAI KHALID K ,  TOTH CAROL A

IPC: A61F2/38 ,  A61K31/728 ,  A61L27/20 ,  A61P19/02

CPC classification number: A61L27/3843 ,  A61K9/0024 ,  A61K9/06 ,  A61K31/573 ,  A61K31/728 ,  A61K31/729 ,  A61K35/28 ,  A61K35/32 ,  A61K38/1841 ,  A61K47/36 ,  A61L27/20 ,  A61L27/227 ,  A61L27/3817 ,  A61L27/3834 ,  A61L27/48 ,  A61L27/52 ,  A61L27/56 ,  A61L2430/06 ,  C08L5/08 ,  A61K2300/00

Abstract: A composite for treating an articular defect includes a hyaluronic acid derivative; and at least one member of the group consisting of a cell, a cellular growth factor and a cellular differentiation factor, which is impregnated in, or coupled to. the hyaluronic acid derivative. In one embodiment, carboxyl functionalities of the hyaluronic acid derivative are each independently derivatized to include an N-acylurea or O-acyl isourea, or both N-acylurea and O-acyl isourea. In another embodiment, the hyaluronic acid derivative is prepared by reacting an uncrosslinked hyaluronic acid with a biscarbodimide in the presence of a pH buffer in a range of between about 4 and about 8. The composite can be used for regenerating or stimulating regeneration of meniscal tissues in a subject in need thereof.

Abstract translation: 用于治疗关节缺损的复合物包括透明质酸衍生物; 以及由细胞，细胞生长因子和细胞分化因子组成的组中的至少一个成员，其被浸渍或偶联。 透明质酸衍生物。 在一个实施方案中，透明质酸衍生物的羧基官能度各自独立地衍生化为包括N-酰基脲或O-酰基异脲，或N-酰基脲和O-酰基异脲二者。 在另一个实施方案中，透明质酸衍生物通过在约4至约8范围内的pH缓冲剂存在下使未交联的透明质酸与双碳酰亚胺反应来制备。该复合物可用于再生或刺激半月板组织的再生 在有需要的受试者中。

公开(公告)号：WO1994026786A1

公开(公告)日：1994-11-24

申请号：PCT/US1994005285

申请日：1994-05-12

Applicant: T CELL SCIENCES, INC. ,  RITTERSHAUS, Charles, W. ,  TOTH, Carol, A.

Inventor： T CELL SCIENCES, INC.

IPC: C07K15/14

CPC classification number: C07K14/7056 ,  A61K38/00 ,  C07K14/705

Abstract: The present invention provides compositions comprising at least one complement moiety and at least one carbohydrate moiety, and methods of producing such compositions. In particular, the compositions of the invention comprise complement proteins related to the complement receptor type 1, and further comprise ligands for intracellular molecules, such as selectins. In a preferred embodiment, the compositions comprise a complement-related protein in combination with the Lewis X antigen or the sialyl Lewis X antigen. The compositions of the invention have use in the diagnosis or therapy of disorders involving complement activity and inflammation. Pharmaceutical compositions are also provided for treating or reducing inflammation mediated by inappropriate complement activity and intercellular adhesion.

Abstract translation: 本发明提供了包含至少一个补体部分和至少一个碳水化合物部分的组合物，以及生产这种组合物的方法。 特别地，本发明的组合物包含与1型补体受体相关的补体蛋白，并且还包含细胞内分子例如选择素的配体。 在优选的实施方案中，组合物包含与Lewis X抗原或唾液酸基路易斯X抗原组合的补体相关蛋白。 本发明的组合物可用于诊断或治疗涉及补体活性和炎症的疾病。 还提供药物组合物用于治疗或减少由不适当的补体活性和细胞间粘附介导的炎症。

公开(公告)号：WO2007070617A1

公开(公告)日：2007-06-21

申请号：PCT/US2006/047658

申请日：2006-12-13

Applicant: ANIKA THERAPEUTICS, INC. ,  SADOZAI, Khalid, K. ,  TOTH, Carol, A. ,  SHERWOOD, Charles, H.

Inventor： SADOZAI, Khalid, K. ,  TOTH, Carol, A. ,  SHERWOOD, Charles, H.

IPC: A61F2/38 ,  A61L27/20 ,  A61K31/728 ,  A61P19/02

CPC classification number: A61K31/728 ,  A61K9/0019 ,  A61K9/0024 ,  A61K9/06 ,  A61K31/573 ,  A61K31/729 ,  A61K35/28 ,  A61K35/32 ,  A61K38/1841 ,  A61K45/06 ,  A61K47/36 ,  A61L27/20 ,  A61L27/227 ,  A61L27/3817 ,  A61L27/3834 ,  A61L27/3843 ,  A61L27/48 ,  A61L27/52 ,  A61L27/56 ,  A61L2430/06 ,  A61M5/178 ,  C08L5/08 ,  A61K2300/00

Abstract: A method for treating an osteochondral defect or a chondral defect in a subject includes implanting a composite in a site of the osteochondral or chondral defect. The composite includes a hyaluronic acid derivative; and at least one member of the group consisting of a cell, a cellular growth factor and a cellular differentiation factor, which is impregnated in, or coupled to, the hyaluronic acid derivative. In one embodiment, carboxyl functionalities of the hyaluronic acid derivative are. each independently derivatized to include an N-acylurea or O-acyl isourea, or both N-acylurea and O-acyl isourea. In another embodiment, the hyaluronic acid derivative is prepared by reacting an uncrosslinked hyaluronic acid with a biscarbodimide in the presence of a pH buffer in a range of between about (4) and about (8). The composite can be used for regenerating or stimulating regeneration of meniscal tissues in a subject in need thereof.

Abstract translation: 用于治疗受试者的骨软骨缺损或软骨缺损的方法包括在骨软骨或软骨缺损的部位植入复合物。 该复合材料包括透明质酸衍生物; 和由透明质酸衍生物浸渍或偶联的由细胞，细胞生长因子和细胞分化因子组成的组中的至少一个成员。 在一个实施方案中，透明质酸衍生物的羧基官能度为。 各自独立地衍生为包括N-酰基脲或O-酰基异脲，或N-酰基脲和O-酰基异脲二者。 在另一个实施方案中，透明质酸衍生物通过在约（4） - （8）之间的pH缓冲剂存在下使未交联的透明质酸与双碳酰亚胺反应来制备。 复合材料可用于再生或刺激有需要的受试者的半月板组织的再生。

公开(公告)号：WO2006029406A3

公开(公告)日：2006-06-22

申请号：PCT/US2005032521

申请日：2005-09-09

Applicant: STRYKER CORP ,  LEE JOHN C ,  TOTH CAROL A

Inventor： LEE JOHN C ,  TOTH CAROL A

IPC: A61K38/18

CPC classification number: A61K38/1875 ,  A61K48/00

Abstract: The present invention provides methods of treating bone cancer, inducing differentiation of bone tumor cells, inhibiting bone tumor growth, inducing bone tumor regression or treating a hyperproliferative cell disorder by administering a pharmaceutically effective amount of a bone morphogenic protein or a nucleic acid encoding the bone morphogenic protein.

Abstract translation: 本发明提供了通过施用药学有效量的骨形态发生蛋白或编码骨的核酸来治疗骨癌，诱导骨肿瘤细胞分化，抑制骨肿瘤生长，诱导骨肿瘤消退或治疗过度增殖性细胞病症的方法 形态发生蛋白。

公开(公告)号：WO1994017822A1

公开(公告)日：1994-08-18

申请号：PCT/US1994001405

申请日：1994-02-08

Applicant: T CELL SCIENCES, INC. ,  REGENTS OF THE UNIVERSITY OF MINNESOTA ,  LEVIN, James, L. ,  REGAL, Jean, F. ,  TOTH, Carol, A.

Inventor： T CELL SCIENCES, INC. ,  REGENTS OF THE UNIVERSITY OF MINNESOTA

IPC: A61K37/64

CPC classification number: A61K9/0078 ,  A61K38/00 ,  C07K14/705

Abstract: The present invention relates to formulations for pulmonary administration by inhalation that comprise a complement inhibitory protein, and uses thereof in the prophylactic or therapeutic treatment of diseases or disorders involving complement, especially diseases or disorders of the lung. In particular, the proteins are complement receptors of fragments thereof or soluble members of the complement receptor family that contain the conserved SCR motif and that are able to inhibit complement activity. More particularly the present invention relates to the direct treatment of certain complement related lung disorders by administering complement receptor proteins via the pulmonary route, in particular, direct delivery to the lungs of a complement receptor protein by aerosolization and subsequent inhalation. The invention also relates to use of a complement inhibitory protein to treat bronchoconstriction or anaphylaxis, or both.

Abstract translation: 本发明涉及包含补体抑制蛋白的吸入肺给药制剂及其在预防或治疗性治疗涉及补体，特别是肺疾病或病症的疾病或病症中的用途。 特别地，蛋白质是其片段的补体受体或补体受体家族的可溶性成员，其含有保守的SCR基序并能够抑制补体活性。 更具体地，本发明涉及通过经由肺途径施用补体受体蛋白质，特别是通过气雾化和随后的吸入直接递送至补体受体蛋白质的肺部来直接治疗某些补体相关性肺病。 本发明还涉及补体抑制蛋白用于治疗支气管收缩或过敏反应或两者的用途。